CMS Proposes Policies That Could Hike Pay For CAR-T Cancer Drug

By John Wilkerson / April 23, 2019 at 8:53 PM

CMS proposed Tuesday (April 23) policy changes that would significantly increase Medicare pay to hospitals for administering expensive CAR-T cancer drugs and make it easier for hospitals to get the maximum possible reimbursement for administering the chimeric antigen receptor T-cell therapies.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

CMS Proposes Policies That Could Hike Pay For CAR-T Cancer Drug

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.